ERIS Lifesciences Ltd

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 March 2026, providing investors with the latest insights into its performance and outlook.

ERIS Lifesciences Ltd has recently undergone a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade. This change reflects evolving market perceptions and adjustments in key financial ratios such as the price-to-earnings (P/E) and price-to-book value (P/BV) multiples. Investors analysing ERIS Lifesciences must consider these valuation dynamics in the context of its sector peers and historical performance to gauge the stock’s price attractiveness and future potential.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

ERIS Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 13 February 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 21 February 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

ERIS Lifesciences Ltd has experienced a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade amid a challenging market backdrop. This recalibration reflects evolving investor sentiment and a reassessment of the company’s price attractiveness relative to its historical averages and peer group within the Pharmaceuticals & Biotechnology sector.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from mildly bearish to bearish trends. The company’s stock price has declined sharply, reflecting deteriorating market sentiment amid a downgrade in its technical grade from Hold to Sell by MarketsMOJO on 9 February 2026.

ERIS Lifesciences Ltd has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite robust revenue and profit before tax growth, operational challenges such as declining inventory and debtor turnover ratios have weighed on the company’s overall financial health, prompting a downgrade in its Mojo Grade from Hold to Sell.

ERIS Lifesciences Ltd., a mid-sized pharmaceutical company with a market capitalisation of ₹20,384 crores, reported a consolidated net profit of ₹99.72 crores for Q3 FY26 (October-December 2025), marking a sharp 17.03% sequential decline from ₹120.19 crores in Q2 FY26. However, on a year-on-year basis, the company posted a respectable 19.05% growth compared to ₹83.76 crores in Q3 FY25. The stock reacted negatively to the results, plunging 6.38% to close at ₹1,414.65 on February 13, 2026, reflecting investor concerns over sequential profitability deterioration despite modest revenue growth.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook as of early February 2026. Despite this cautious tone, the stock has demonstrated resilience with a 2.57% gain on 13 Feb 2026, closing at ₹1,505.90, supported by a blend of mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages.

ERIS Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold as of 9 February 2026, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality. This shift comes amid a backdrop of mixed returns relative to the Sensex and a strengthening operational performance in recent quarters.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a nuanced change in market sentiment. Despite a positive day change of 2.92%, the stock’s technical indicators present a complex picture that investors should carefully analyse before making decisions.

ERIS Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the latest insights into its performance and outlook.

ERIS Lifesciences Ltd has seen its investment rating downgraded from Hold to Sell as of 19 Jan 2026, driven primarily by deteriorating technical indicators and valuation concerns despite solid financial performance. The company’s Mojo Score has declined to 44.0, reflecting a shift in market sentiment and caution among investors.

ERIS Lifesciences Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall quality. This recalibration follows a detailed assessment of the company’s recent performance, market positioning, and comparative returns, signalling cautious optimism among analysts and investors alike.

ERIS Lifesciences Ltd has experienced a notable shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a recent downgrade in daily moving averages and a 1.58% decline in share price, the stock’s longer-term metrics suggest cautious optimism for investors navigating the Pharmaceuticals & Biotechnology sector.